CoChat

Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer

Shaw, VE, Naisbitt, DJ, Costello, E, Greenhalf, W, Park, BK, Neoptolemos, JP, Middleton, GW · 2010 · Expert Review of Vaccines
Cited by 40

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

GV1001 is a telomerase-specific, promiscuous class II peptide vaccine which is currently in an advanced stage of clinical development. This article reviews the biological rationale underpinning the design of ongoing studies with the vaccine as well as its immunogenicity and clinical activity. It places GV1001 in the context of other immunotherapeutic approaches targeting telomerase and assesses the chances of the vaccine becoming a future standard of care in the treatment of cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1586/erv.10.92

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 40

Metadata

Authors
Shaw, V., Naisbitt, D., Costello, E., Greenhalf, W., Park, B., Neoptolemos, J., & Middleton, G.
Venue
Expert Review of Vaccines
Published
2010-09
Volume
9
Issue
9
Pages
1007-1016
ISSN
  • 1476-0584 (ISSN-L)
  • 1744-8395
OpenAlex
W2129104475
Cited by
40
References
13
FWCI
0.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. https://app.cochat.ai/papers/10.1586/erv.10.92
The paper
Shaw, V., Naisbitt, D., Costello, E., Greenhalf, W., Park, B., Neoptolemos, J., & Middleton, G. (2010). Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Review of Vaccines. https://doi.org/10.1586/erv.10.92

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.